CTLA4 and hereditary clear cell renal cell carcinoma: Immune checkpoint blockade therapy that impedes the PD-1/PD-L1 and anti-CTLA-4 pathway can increase OS in patients with advanced melanoma, non-small-cell lung cancer, urothelial cancer, renal cell carcinoma and other cancer types [31–35].